·5 min read
China Biotech Weekly #13: The BIOSECURE Countdown — 9 Months Until the BCC List Reshapes China Pharma Partnerships
The OMB has 9 months to publish the BCC list. We break down the three designation categories, track which companies face real exposure, and analyze what AstraZeneca's $18.5B CSPC deal structure tells us about pricing China risk in 2026.
BIOSECUREBCC ListAstraZenecaWuXiBGI